WW WW International Inc.
Price Chart
Executive Summary
WW International announced an expanded collaboration with Novo Nordisk to offer eligible Med+ members discounted subscription pricing for Wegovy, saving up to $1,200 annually. This enhances access to GLP-1 treatment and reinforces WW's integrated weight health model, though no financial impact on revenue or profitability was quantified.
Actionable Insight
Monitor WW's future earnings reports for Med+ membership growth trends and any update on partnership-driven revenue. While this improves patient affordability, it does not directly boost WW's top line unless it translates into higher enrollment or retention.
Key Facts
- WW International and Novo Nordisk expanded their collaboration to offer subscription pricing for Wegovy to eligible Med+ members.
- Members can save up to $1,200 per year, or up to $100/month on pens and $50/month on pills, via pre-paid 3, 6, or 12-month plans.
- The offer applies to all Wegovy pen doses and 9 mg/25 mg pill doses; existing limited-time offers also remain available.
- WW is a NovoCare® Recognized Care Provider and emphasizes combining medication with lifestyle support for better outcomes.
- No financial terms, revenue impact, or membership uptake figures were disclosed.
Financial Impact
No direct financial impact disclosed; potential indirect benefit from increased Med+ membership demand.
Risk Factors
- No material financial benefit if increased access does not drive higher Med+ adoption.
- Dependence on Novo Nordisk's supply and pricing policies, which are outside WW's control.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3265364 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 4, 2026
5d ago
|
DEFA14A
| $17.27 $16.25 | ▼ −5.88% | ▼ −3.28% | $17.19 (−0.43%) |
|
May 27, 2026
13d ago
|
Insider Cluster
| $17.10 $16.62 | ▼ −2.81% | ▼ −3.05% | $17.19 (+0.53%) |
|
May 15, 2026
25d ago
|
DEFA14A
| $10.03 $9.36 | ▼ −6.68% | ▼ −6.03% | $17.19 (+71.39%) |
|
Apr 27, 2026
6w ago
|
8-K
| $10.51 $9.80 | ▼ −6.76% | ▼ −6.27% | $17.19 (+63.56%) |
|
Apr 23, 2026
6w ago
|
Press Release
| $9.27 $10.51 | ▲ +13.38% | ▲ +13.21% | $17.19 (+85.44%) |
|
Apr 20, 2026
7w ago
|
8-K
| $10.00 $9.12 | ▼ −8.80% | ▼ −8.15% | $17.19 (+71.90%) |
|
Apr 17, 2026
7w ago
|
8-K
| $10.00 $9.12 | ▼ −8.80% | ▼ −8.15% | $17.19 (+71.90%) |
|
Apr 7, 2026
9w ago
|
8-K
| $11.62 $11.30 | ▼ −2.75% | ▼ −5.29% | $17.19 (+47.93%) |
|
Apr 3, 2026
9w ago
|
8-K
| $12.01 $11.62 | ▲ +3.25% | ▲ +3.31% | $17.19 (−43.13%) |
|
Mar 31, 2026
10w ago
|
Press Release
| $13.74 $14.06 | ▲ +2.33% | ▲ +1.58% | $17.19 (+25.11%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access